Achievement
year
Authors
Language
Paper Title
Blom DJ*, Harada-Shiba M, Rubba P, Gaudet D, Kastelein JJP, Charng MJ, Pordy R, Donahue S, Ali S, Dong YP, Khilla N, Banerjee P, Baccara-Dinet M, Rosenson RS.
J Am Coll Cardiol 2020;76:131-42. (IF: 20.589)
Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia The ODYSSEY HoFH Trial.
Chan CS, Lin YS, Lin YK, Chen YC, Kao YH, Hsu CC, Chen SA, Chen YJ*.
Transl Res 2020;223:25-39. (IF: 5.411)
Atrial arrhythmogenesis in a rabbit model of chronic obstructive pulmonary disease.
Chan YH, Chao TF, Chen SW, Lee HF, Yeh YH, Huang YC, Chang SH, Kuo CT, Lip GYH, Chen SA.
Heart Rhythm 2020;17:2102-10. (IF:5.731)
Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation.
Chan YH, Chao TF*, Lee HF, Yeh YH, Yeh CH, Huang YC, Chang SH, Kuo CT, Lip GYH, Chen SA.
J Am Coll Cardiol 2020;76:1808-10. (IF: 20.589)
Impacts of Different Renal Function Estimation Formulas on Dosing of DOACs and Clinical Outcomes.
Chan YH, Chuang C, Chan CC, Lee HF, Huang YC, Huang YT, Chang SH, Wang CL, Chao TF*, Kuo CT, Yeh YH, Chen SA.
Cardiovasc Diabetol 2020;19:30. (IF:7.332)
Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation.
Chan YH, Lee HF, Li PR, Liu JR, Chao TF, Wu LS, Tung YC, Yeh YH, Kuo CT, See LC*, Lip GYH*.
Cardiovasc Diabetol 2020;19:63. (IF:7.332)
Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants.
Chan YH*, Wu LS, See LC, Liu JR, Chang SH, Chao TF, Yeh YH, Kuo CT, Lee HF*, Lip GYH*.
J Clin Endocrinol Metab 2020;105:2893-904. (IF: 5.399)
Direct Oral Anticoagulants in Atrial Fibrillation Patients With Concomitant Hyperthyroidism.
Chang CC , Kogame N, Onuma Y, Byrne RA, Capodanno D, Windecker S, Morel MA, Cutlip DE, Krucoff MW, Stone GW, Lansky A, Mehran R, Spitzer E, Fraser AG, Baumbach A, Serruys PW*.
EuroIntervention 2020;15:1190-8. (IF:3.993)
Defining device success for percutaneous coronary intervention trials: a position statement from the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology.
Chang CC, Chichareon P, Modolo R, Takahashi K , Kogame N, Tomaniak M, Gao C, Royaards KJ, Cequier A, Oldroyd K, Steg PG, Hamm C, Juni P, Valgimigli M, Windecker S, Onuma Y, Stables R, van Geuns RJ, Serruys PW*.
Eur Heart J-Cardiovasc Pharmacother 2020;6:22-30. (IF: 6.696)
Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study.
Chang CC, Lin YJ*.
J Chin Med Assoc 2020;83:517. (IF: 2.170)
Disease-Specific Care certification program of acute myocardial infarction: Bring owls to Athens?